美国格伦马克制药公司推出聚乙二醇3350粉末溶液，17克/帽（非处方药）-动脉网

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)

CISION 等信源发布 2025-03-10 20:03



可切换为仅中文







MAHWAH, N.J.

马瓦，新泽西州

，

March 10, 2025

2025年3月10日

/PRNewswire/ -- Glenmark Therapeutics Inc.,

/PRNewswire/ -- 格伦马克治疗学公司，

USA

美国

(Glenmark) is pleased to announce the launch

（格伦马克）很高兴地宣布推出

of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX®

聚乙二醇3350粉末溶液，17克/帽（非处方药）；与MiraLAX®的活性成分对比

Powder for Solution, 17 grams of Bayer HealthCare LLC.

溶液用粉末，17克，拜耳健康护理有限责任公司。

According to Nielsen® syndicated data for the latest 52 weeks' period ending

根据尼尔森®联合数据，截至最近52周的期间结束时

February 22, 2025

2025年2月22日

, the MiraLAX® Powder for Solution, 17 grams (OTC) market

`, MiraLAX® Powder for Solution，17克（非处方药）市场`

achieved annual sales of approximately

实现了约年度销售额

$555.7 million

5.557亿美元

Commenting on the launch,

在发布之际评论道，

Marc Kikuchi

马克·木村

, President & Business Head,

，总裁兼业务主管，

North America

北美

said,

说，

'We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.'.

“我们很高兴宣布推出聚乙二醇3350粉剂，每勺17克，以满足市场对这一类别新供应商日益增长的需求。此次添加彰显了我们致力于满足市场需求，并为客户提供高质量非处方解决方案的承诺。”

For product information and how to purchase, please visit:

有关产品信息及购买方式，请访问：

https://glenmarkpharma-us.com/peg3350

。

About Glenmark Pharmaceuticals Ltd.

关于格伦马克制药有限公司

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.

格伦马克制药有限公司（BSE：532296）（NSE：GLENMARK）是一家以研发为主导的全球制药公司，业务涵盖品牌药、仿制药和非处方药领域，专注于呼吸系统、皮肤病学和肿瘤学治疗领域。该公司在四大洲拥有11个世界级的生产设施，并在80多个国家开展业务。

Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in .

Scrip 100 将 Glenmark 列为 2023 年按药品销售额排名的前 100 家生物制药公司之一；而 Generics Bulletin 则将其列为 2024 年按销售额排名的前 50 家仿制药和生物类似药公司之一。Glenmark 的温室气体 (GHG) 减排目标在 2023 年获得了科学基础目标倡议 (SBTi) 的批准，使其成为第二家获此认可的制药公司。

India

印度

to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit

为实现这一目标。在过去的十年中，该组织通过其企业社会责任干预措施已经影响了超过330万人的生活。欲了解更多信息，请访问

www.glenmarkpharma.com

. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

您可以在LinkedIn（Glenmark Pharmaceuticals）和Instagram（glenmark_pharma）上关注我们。

References

参考文献

Glenmark's Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) is only marketed for the indications listed in Glenmark's approved drug facts label.

Glenmark的聚乙二醇3350粉末溶液，17克/帽（非处方药）仅用于Glenmark批准的药物事实标签中列出的适应症。

This product is not manufactured or distributed by Bayer HealthCare LLC, distributor of MiraLAX® Powder for Solution, Osmotic Laxative, and owner of the registered trademark MiraLAX®. [Bayer HealthCare LLC does not make or license Glenmark's product.]

本产品并非由拜耳健康护理有限责任公司制造或分销，该公司是MiraLAX® Powder for Solution、渗透性泻药的分销商，并拥有注册商标MiraLAX®。[拜耳健康护理有限责任公司不生产或许可格伦马克的产品。]

Market includes brand and all available therapeutic equivalents. Note: Nielsen syndicated data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications..

市场包括品牌及所有可用的治疗等效品。注意：Glenmark获得的Nielsen联合数据仅适用于所有获批的RLD适应症。Glenmark的产品仅获批用于Glenmark标签中列出的适应症，并未针对所有RLD适应症进行销售。

*Nielsen® NIQ Discover; Syndicated Data for Period Ending

尼尔森® NIQ Discover；截至日期的联合数据

February 22, 2025

2025年2月22日

Logo:

标志：

https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg

SOURCE Glenmark Pharmaceuticals Ltd

来源：格伦马克制药有限公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？